

Roche Announces New Ten-Year Data of Perjeta-Based Regimen for HER2-Positive Early Breast Cancer

TOKYO, May 13, 2025 -- [Chugai Pharmaceutical Co., Ltd.](#) (TOKYO: 4519) announced that Roche issued a press release today, regarding ten-year data from global Phase III study (APHINITY study) of the combination of Perjeta® (pertuzumab), Herceptin® (trastuzumab) and chemotherapy (the Perjeta-based regimen) for HER2-positive early breast cancer. The full data will be presented at the 2025 European Society for Medical Oncology Breast Cancer Congress on May 15, 2025.

Please refer to the link below for details of the press release:

Ten-year APHINITY data show Roche's Perjeta-based regimen reduced the risk of death by 17% in people with HER2-positive early-stage breast cancer

<https://www.roche.com/media/releases/med-cor-2025-05-13>

Trademarks used or mentioned in this release are protected by laws.

###